Scientists Identify a More Accurate Blood Test for Predicting Heart Attacks and Strokes

Why Measuring Apolipoprotein B Outperforms Traditional Lipid Tests

According to НВ — Техно: July 6, 4:30 PM

Researchers have demonstrated that measuring apolipoprotein B (apoB) is a more reliable way to identify patients who need intensive therapy to lower their risk of heart attacks and strokes. Using computer modeling on a dataset of 250,000 adults, the study found that targeting an apoB level below 2.04 mmol/L allows doctors to fine-tune medication doses with greater precision. This biomarker counts the exact number of harmful cholesterol-carrying particles in the blood, which directly contribute to the buildup of plaque in artery walls.

For comparison, traditional targets focus on low-density lipoprotein (LDL) cholesterol below 2.59 mmol/L or non-high-density lipoprotein (non-HDL) cholesterol under 3.05 mmol/L. However, the scientists argue that apoB testing offers a more accurate method for pinpointing individuals who require extra medical attention. Although the apoB test requires additional lab work and raises upfront diagnostic costs, it proves cost-effective for healthcare systems in the long run. These expenses are offset by fewer hospitalizations due to cardiac events.

Modern Trends in Cardiovascular Disease Management

A growing global trend involves starting lipid-lowering therapy at younger ages, which further underscores the need for early diagnosis and treatment adjustments. The researchers urge wider adoption of apoB testing to improve patient outcomes and reduce the burden of serious cardiovascular conditions.

Using apoB as a biomarker for cardiovascular risk assessment could reshape how heart disease is prevented and managed. This study highlights the value of personalized therapy, leading to better results for patients. As cardiovascular diseases become more prevalent, integrating advanced diagnostic tools like the apoB test is increasingly critical for the medical community.

In addition to advancements in cardiovascular diagnostics, innovations in neurodegenerative disease detection are also emerging. For instance, recent developments in artificial intelligence have enabled the identification of Alzheimer's disease through retinal imaging. This approach not only enhances early diagnosis but also complements the efforts in personalized medicine. To learn more about how AI is transforming the landscape of disease detection, read about its application in detecting Alzheimer's from eye scans.